Imagine finding a tiny needle in a haystack, but the needle is a piece of cancer DNA floating in your blood. Instead of expensive and slow sequencing, this tool uses a specialized chip and AI to spot these markers quickly. It's like a high-tech filter that tells doctors if a patient has cancer or just a lung infection without needing a surgical biopsy.
Lung cancer is often detected too late for cure, and current screening tools like LDCT produce inconclusive results. Additionally, there is no rapid, non-invasive way to predict if a patient will respond to a specific therapy.
A custom diagnostic microarray chip (LUMEN chip) and a machine learning-based algorithm for classifying blood samples as healthy or cancerous.
If you are a diagnostic lab dealing with high costs and slow turnaround for genetic sequencing — this project developed a custom microarray chip and AI algorithm that provides a more affordable and scalable way to detect lung cancer with over 90% accuracy.
If you are a clinic dealing with the fact that 70% of patients are diagnosed too late for curative treatment — this project developed a non-invasive liquid biopsy assay that detects early-stage (I-II) lung cancer to improve patient outcomes.
If you are a pharma company dealing with 50% of patients receiving suboptimal treatment due to poor response prediction — this project developed a companion diagnostic tool to predict therapy response and assess treatment effectiveness.
Based on available project data, the LUMEN system eliminates the need for DNA sequencing, which makes the solution more affordable than current technologies.
The project has already developed a custom diagnostic microarray (LUMEN chip) and an AI algorithm, describing the solution as scalable.
Based on available project data, JaxBio uses proprietary chemo-enzymatic labelling technology and a custom-designed chip, though specific licensing terms are not listed.
The overall objective is to bring forward a diagnostic platform that achieves both CE and FDA approval.
The project period runs from 2024-11-01 to 2026-10-31, during which they intend to conduct clinical trials and complete chip development.
The project is led by a single SME, JaxBio Technologies Ltd from Israel. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization and product development rather than academic exploration.
Contact JaxBio Technologies Ltd regarding the LUMEN diagnostic platform
Contact us to explore licensing or partnership opportunities with JaxBio
